Fig. 7

RNAseq analysis of the effect of bexarotene on the PFC transcriptome in cisplatin treated animals. Mice were treated with cisplatin and bexarotene and transcriptome analysis of the PFC was performed after the 5th dose of bexarotene and IPA pathway analysis was performed on the upregulated genes (padj < 0.1). a The dot plot shows the top up-regulated pathways identified in PFC from mice treated with cisplatin + bexarotene as compared to cisplatin alone using the IPA tool. The size of the dot represents gene count and the color represents the p value. b The heat map shows the expression profile of the differentially expressed genes related to the TR/RXR, LXR/RXR, and PPAR/RXR pathways from the comparison of PFC from mice treated with cisplatin versus cisplatin + bexarotene. c The bar diagram shows the functional enrichment related to the nervous system and development function identified in PFC from mice treated with cisplatin + bexarotene using the IPA tool. d Top upstream regulators predicted by the IPA tool to be causing bexarotene-induced gene expression changes